Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$14.1 million.

  • Phathom Pharmaceuticals' Free Cash Flow rose 7777.01% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$225.4 million, marking a year-over-year increase of 901.8%. This contributed to the annual value of -$266.9 million for FY2024, which is 9172.28% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Free Cash Flow of -$14.1 million as of Q3 2025, which was up 7777.01% from -$62.8 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Free Cash Flow high stood at -$14.1 million for Q3 2025, and its period low was -$85.0 million during Q1 2025.
  • In the last 4 years, Phathom Pharmaceuticals' Free Cash Flow had a median value of -$44.3 million in 2023 and averaged -$47.7 million.
  • In the last 5 years, Phathom Pharmaceuticals' Free Cash Flow plummeted by 21868.41% in 2024 and then soared by 7777.01% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Free Cash Flow (Quarter) stood at -$41.5 million in 2022, then dropped by 6.8% to -$44.3 million in 2023, then tumbled by 43.34% to -$63.5 million in 2024, then soared by 77.72% to -$14.1 million in 2025.
  • Its Free Cash Flow was -$14.1 million in Q3 2025, compared to -$62.8 million in Q2 2025 and -$85.0 million in Q1 2025.